Remove Clinical Trials Remove Collective Remove Patients Remove Safety
article thumbnail

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. In addition, 66.7%

article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

article thumbnail

Knowde Group Inc.™ Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Cannabis Law Report

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

article thumbnail

Press Release: Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes

Cannabis Law Report

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.